NS5A Inhibitors

Why A Change In A Bristol-Myers Hepatitis C Trial Has Big Implications

Why A Change In A Bristol-Myers Hepatitis C Trial Has Big Implications

Forbes

Bristol Hep C Trial Change Has Big Implications

Bristol Hep C Trial Change Has Big Implications

Pharmalot

Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668.

Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668.

BusinessWire